Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $24.5 million.

  • Veracyte's Cost of Revenue rose 815.05% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.0 million, marking a year-over-year increase of 331.59%. This contributed to the annual value of $95.4 million for FY2024, which is 596.71% down from last year.
  • Veracyte's Cost of Revenue amounted to $24.5 million in Q3 2025, which was up 815.05% from $25.3 million recorded in Q2 2025.
  • Veracyte's Cost of Revenue's 5-year high stood at $26.1 million during Q1 2023, with a 5-year trough of $16.3 million in Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $24.2 million (2024), whereas its average is $23.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 9780.92% in 2021, then plummeted by 898.58% in 2024.
  • Veracyte's Cost of Revenue (Quarter) stood at $22.2 million in 2021, then rose by 8.62% to $24.1 million in 2022, then grew by 4.7% to $25.3 million in 2023, then fell by 1.73% to $24.8 million in 2024, then decreased by 1.49% to $24.5 million in 2025.
  • Its last three reported values are $24.5 million in Q3 2025, $25.3 million for Q2 2025, and $24.5 million during Q1 2025.